WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer

Kench JG, Amin MB, Berney DM, Compérat EM, Cree IA, Gill AJ, Hartmann A, Menon S, Moch H, Netto GJ, Raspollini MR, Rubin MA, Tan PH, Tsuzuki T, Turjalic S, van der Kwast TH, Zhou M, Srigley JR (2022)

Publication Type: Journal article, Review article

Publication year: 2022

Journal

DOI: 10.1111/his.14711

Abstract

The fifth edition of the WHO Classification of Tumours of the Urinary and Male Genital Systems encompasses several updates to the classification and diagnosis of prostatic carcinoma as well as incorporating advancements in the assessment of its prognosis, including recent grading modifications. Some of the salient aspects include: (1) recognition that prostatic intraepithelial neoplasia (PIN)-like carcinoma is not synonymous with a pattern of ductal carcinoma, but better classified as a subtype of acinar adenocarcinoma; (2) a specific section on treatment-related neuroendocrine prostatic carcinoma in view of the tight correlation between androgen deprivation therapy and the development of prostatic carcinoma with neuroendocrine morphology, and the emerging data on lineage plasticity; (3) a terminology change of basal cell carcinoma to “adenoid cystic (basal cell) cell carcinoma” given the presence of an underlying MYB::NFIB gene fusion in many cases; (4) discussion of the current issues in the grading of acinar adenocarcinoma and the prognostic significance of cribriform growth patterns; and (5) more detailed coverage of intraductal carcinoma of prostate (IDC-P) reflecting our increased knowledge of this entity, while recommending the descriptive term atypical intraductal proliferation (AIP) for lesions falling short of IDC-P but containing more atypia than typically seen in high-grade prostatic intraepithelial neoplasia (HGPIN). Lesions previously regarded as cribriform patterns of HGPIN are now included in the AIP category. This review discusses these developments, summarising the existing literature, as well as the emerging morphological and molecular data that underpins the classification and prognostication of prostatic carcinoma.

Authors with CRIS profile

Involved external institutions

New South Wales Department of Health Australia (AU) The University of Tennessee Health Science Center United States (USA) (US) Royal London Hospital / London Infirmary United Kingdom (GB) Universität Wien / University of Vienna Austria (AT) International Agency for Research on Cancer (IARC) France (FR) University of Sydney (USYD) Australia (AU) Homi Bhabha National Institute (HBNI) India (IN) Universitätsspital Zürich (USZ) Switzerland (CH) University of Alabama at Birmingham (UAB) United States (USA) (US) Careggi University Hospital / Azienda Ospedaliero Universitaria Careggi Italy (IT) Universität Bern Switzerland (CH) Singapore General Hospital Singapore (SG) Aichi Medical University Hospital / 愛知医科大学病院 Japan (JP) Royal Marsden Hospital / The Royal Marsden NHS Foundation Trust United Kingdom (GB) University of Toronto Canada (CA) Tufts Medical Center United States (USA) (US)

How to cite

APA:

Kench, J.G., Amin, M.B., Berney, D.M., Compérat, E.M., Cree, I.A., Gill, A.J.,... Srigley, J.R. (2022). WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology. https://dx.doi.org/10.1111/his.14711

MLA:

Kench, James G., et al. "WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer." Histopathology (2022).

BibTeX: Download